Table 4.

JAKi trial in patients with dermatomyositis.

Disease type	Inhibitor	Target	Administration	Phase	Study number
DM	Tofacitinib	JAK1 JAK3	Oral	Phase I	NCT03002649

Clinical trial program according to clinicaltrials.gov. DM, dermatomyositis.